一个架构上合理的血静止器,用于快速停止抗凝治疗的大量出血
Vivian K Lee1,2,3,4, Taewoo Lee1,2,3,4, Amrit Ghosh1,4
1Center for Engineered Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
概括
灵感来自肺部架构的新型胆酸盐血静止剂通过快速吸收血液并激活血小板通路,有效地阻止严重出血. 这种工程设备在控制出血方面表现有前途,即使是用抗凝剂治疗.
科学领域:
- 生物材料工程 生物材料工程
- 血液静止研究 血液静止研究
- 翻译医学是一种翻译医学.
背景情况:
- 严重出血需要先进的静血装置,特别是随着抗凝剂使用的增加.
- 目前的血静止剂可能缺乏优化的结构和明显的凝血路径激活.
- 新兴的医疗需求需要下一代静血解决方案.
研究的目的:
- 设计一种具有增强血液接触和独特的凝血激活的新型基托桑血静止剂.
- 在临床前和临床模型中研究微孔胆装置的静血效果.
- 探索血液静止器作用的分子机制,包括血小板受体相互作用.
主要方法:
- 基托血压器是用一个曲的,球形的微孔结构来设计的,模仿肺气泡.
- 评估血液吸收,血小板和纤维素微血栓度.
- 评估小鼠肝脏,猪肝脏和动脉损伤以及人类放射性动脉穿刺的静血性能.
- 通过托尔类受体2 (TLR2) 直接激活血小板的研究.
主要成果:
- 工程造血静止器显示出快速的血液吸收和缩的血小板和纤维素.
- 在多种伤害模型中,在几分钟内显著减少血液损失和有效控制出血.
- 即使在抗凝固药物治疗的存在下,也可以实现血液静止.
- 证实了基托血静止剂对血小板TLR2的直接激活,挑战了以前的教条.
结论:
- 与经典设备相比,工程微孔酸盐血静止器提供了优越的血静止功能.
- 该设备的有效性源于其架构和通过TLR2直接激活血小板.
- 这种方法将工程设计与分子理解相结合,用于改进静血装置,解决关键医疗需求.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
01:05Introduction to Hemostasis
7.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.8K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:22Formation of the Platelet Plug
6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K